antimuscarinic deprescribing; anticholinergic deprescribing
Jump to navigation
Jump to search
Introduction
- insufficient evidence that deprecribing antimuscarinic agents improve cognition in older adults with or without prior cognitive impairment (because the evidence from randomized controlled trials is of very low certainty)
- no evidence from randomized controlled trials that deprecribing antimuscarinic agents interventions improve other clinical outcomes includingmortality, quality of life, physical function, institutionalisation, falls, cardiovascular disease, or neurobehavioral outcomes[1]
More general terms
References
- ↑ 1.0 1.1 Taylor-Rowan M, Alharthi AA, Noel-Storr AH et al Anticholinergic deprescribing interventions for reducing risk of cognitive decline or dementia in older adults with and without prior cognitive impairment. Cochrane Database Syst Rev. 2023 Dec 8;12(12):CD015405. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38063254 Review.